Cargando…
A practical guide about biosimilar data for health care providers treating inflammatory diseases
To make informed decisions about the safety, efficacy, and clinical utility of a biosimilar, health care providers should understand the types and be able to analyze data generated from a biosimilar development program. This article reviews the biosimilar guidelines, the biosimilar development proce...
Autores principales: | Markenson, Joseph, Alvarez, Daniel F, Jacobs, Ira, Kirchhoff, Carol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338847/ https://www.ncbi.nlm.nih.gov/pubmed/28280299 http://dx.doi.org/10.2147/BTT.S122335 |
Ejemplares similares
-
Drug tendering: drug supply and shortage implications for the uptake of biosimilars
por: Dranitsaris, George, et al.
Publicado: (2017) -
Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology
por: Tinsley, Sara M., et al.
Publicado: (2018) -
Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser, John RP, et al.
Publicado: (2017) -
Patient attitudes and understanding about biosimilars: an international cross-sectional survey
por: Jacobs, Ira, et al.
Publicado: (2016) -
Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2016)